Overview

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

Status:
Recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic CAH subjects up to 76 weeks of treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Spruce Biosciences